Results 231 to 240 of about 90,745 (249)

Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs

Nature Reviews Drug Discovery, 2018
Delphine Charvin, Robert A Hauser, Olivier Rascol   +2 more
exaly  

Priorities in Parkinson's disease research

Nature Reviews Drug Discovery, 2011
Thomas Gasser, Andres Lozano, Olivier Rascol   +2 more
exaly  

Discriminating α-synuclein strains in Parkinson’s disease and multiple system atrophy

Nature, 2020
Mohammad Shahnawaz, Sandra Pritzkow, Wolfgang Singer   +2 more
exaly  

Novel pharmacological targets for the treatment of Parkinson's disease

Nature Reviews Drug Discovery, 2006
Anthony H V Schapira, Jonathan M Brotchie, Frédéric Calon   +2 more
exaly  

Parkinson’s disease

Nursing Older People, 2016
openaire   +4 more sources

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

Lancet, The, 2017
Dilan S Athauda, Simon S Skene, John Dickson   +2 more
exaly  

Development of Multifunctional Molecules as Potential Therapeutic Candidates for Alzheimer’s Disease, Parkinson’s Disease, and Amyotrophic Lateral Sclerosis in the Last Decade

Chemical Reviews, 2019
Geewoo Nam, Hyuck Jin Lee, Mi Hee Lim
exaly  

Parkinson disease

JAAPA, 2023
openaire   +2 more sources

Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial

Lancet, The, 2014
Jeffrey L Cummings, Anne Corbett, Rohit Dhall   +2 more
exaly  

Long-term safety and tolerability of ProSavin, a lentiviral vector-based gene therapy for Parkinson's disease: a dose escalation, open-label, phase 1/2 trial

Lancet, The, 2014
Philip C Buttery, Philippe Le Corvoisier, David P Breen   +2 more
exaly